OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

Abstract: Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB chimeric antigen receptor (CAR) T-cell product approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We present the OUTREACH primary analysis, evaluating the safety and efficacy of outpatient monitori...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Yuliya Linhares, Cesar O. Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan C. Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ana Kostic, Min Vedal, Ken Ogasawara, Ariel Avilion, Ricardo Espinola, Brenda Yuan, Bassam Mattar
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2024-12-01
Schriftenreihe:	Blood Advances
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2473952924005718
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!